[HTML][HTML] The low-risk profile in pulmonary arterial hypertension. Time for a paradigm shift to goal-oriented clinical trial endpoints?
J Weatherald, A Boucly, S Sahay… - American journal of …, 2018 - atsjournals.org
Pulmonary arterial hypertension (PAH) is a devastating condition characterized by
progressive symptoms, right heart failure, and death (1, 2). In the 1980s, the NIH Registry for …
progressive symptoms, right heart failure, and death (1, 2). In the 1980s, the NIH Registry for …
[HTML][HTML] Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
M Humbert, HW Farber, HA Ghofrani… - European …, 2019 - Eur Respiratory Soc
Background Current pulmonary hypertension treatment guidelines recommend use of a risk
stratification model encompassing a range of parameters, allowing patients to be …
stratification model encompassing a range of parameters, allowing patients to be …
Risk stratification in pulmonary arterial hypertension
J Weatherald, A Boucly, O Sitbon - Current Opinion in Pulmonary …, 2018 - journals.lww.com
Risk stratification in pulmonary arterial hypertension : Current Opinion in Pulmonary Medicine
Risk stratification in pulmonary arterial hypertension : Current Opinion in Pulmonary Medicine …
Risk stratification in pulmonary arterial hypertension : Current Opinion in Pulmonary Medicine …
[HTML][HTML] REVEAL risk score in patients with chronic thromboembolic pulmonary hypertension receiving riociguat
RL Benza, HW Farber, A Frost, E Grünig… - The Journal of Heart and …, 2018 - Elsevier
Background The REVEAL risk score (RRS) was developed to predict survival in patients
with pulmonary arterial hypertension (PAH), based on multiple patient characteristics …
with pulmonary arterial hypertension (PAH), based on multiple patient characteristics …
Assessing risk in pulmonary arterial hypertension: what we know, what we don't
RL Benza, HW Farber, M Selej… - European …, 2017 - Eur Respiratory Soc
Despite improvement in short-term survival, pulmonary arterial hypertension (PAH) remains
an incurable disease with an unacceptable median survival of 7 years [1]. In the USA, the …
an incurable disease with an unacceptable median survival of 7 years [1]. In the USA, the …
Risk assessment in pulmonary arterial hypertension patients: the long and short of it
RL Benza, LC Lohmueller… - Advances in …, 2018 - meridian.allenpress.com
Pulmonary arterial hypertension (PAH) is a chronic and rapidly progressive disease that is
characterized by extensive narrowing of the pulmonary vasculature, leading to increases in …
characterized by extensive narrowing of the pulmonary vasculature, leading to increases in …
[HTML][HTML] Risk assessment tools in pulmonary arterial hypertension. Prognosis for prospective trials?
HW Farber, RL Benza - American journal of respiratory and critical …, 2018 - atsjournals.org
Treatment of pulmonary arterial hypertension (PAH) has come a long way in the last two
decades. We have improved functional status and survival, developed new therapies, begun …
decades. We have improved functional status and survival, developed new therapies, begun …
[HTML][HTML] Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE
RL Benza, PA Corris, JR Klinger, D Langleben… - International journal of …, 2020 - Elsevier
Background RESPITE evaluated patients with pulmonary arterial hypertension and an
inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to …
inadequate response to phosphodiesterase type 5 inhibitors (PDE5i) who switched to …
Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology/European Respiratory Society goal-orientated risk reduction strategy …
C Kaymaz, OY Akbal, A Hakgor… - Pulmonary …, 2018 - journals.sagepub.com
Despite the significant mortality and mobidity benefits being obtained with the targeted
therapies in patients with pulmonary arterial hypertension (PAH), mid-to long-term survival of …
therapies in patients with pulmonary arterial hypertension (PAH), mid-to long-term survival of …
[HTML][HTML] The Evolution of Risk Assessment in Pulmonary Arterial Hypertension
S Murthy, R Benza - Methodist DeBakey cardiovascular journal, 2021 - ncbi.nlm.nih.gov
Pulmonary arterial hypertension (PAH) is a chronic debilitating disease that carries an
unacceptably high morbidity and mortality rate despite improved survival with modern …
unacceptably high morbidity and mortality rate despite improved survival with modern …